# Endo Statin Rather Than Hormone Therapy Postmenopausal Women

> The guideline recommends statin therapy over hormone therapy for dyslipidemia management in postmenopausal women. Consider this approach when encountering a postmenopausal woman with dyslipidemia, choosing between statin and hormone therapy, or assessing first-line lipid treatment in menopause.

- Skill: `dromlakhani/endo-statin-rather-than-hormone-therapy-postmenopausal-women` (Agent Skill)
- Install (CLI): `npx skillmds@latest add dromlakhani/endo-statin-rather-than-hormone-therapy-postmenopausal-women`
- Raw SKILL.md: https://api.skillmd.com/api/skills/dromlakhani/endo-statin-rather-than-hormone-therapy-postmenopausal-women/raw
- Safety review: pending (external: skill-scanner PASS, skillspector PASS)
- Works with: Claude Code, Claude.ai, OpenAI Codex
- Category: Coding & Dev Tools
- Author: dromlakhani (https://skillmd.com/u/dromlakhani)
- Updated: 2026-09-08
- Page: https://skillmd.com/skills/dromlakhani/endo-statin-rather-than-hormone-therapy-postmenopausal-women

---


# Treat dyslipidemia with statin therapy rather than hormone therapy in postmenopausal women

## STEP 1 — Gather Information
Confirm menopausal status (postmenopausal, defined as ≥12 months amenorrhea or age >55 with symptoms), obtain fasting lipid panel (LDL-C, HDL-C, TG, total cholesterol), assess for contraindications to hormone therapy (history of VTE, stroke, active liver disease, unexplained vaginal bleeding, breast cancer), and evaluate statin contraindications (pregnancy, active liver disease, CK >5×ULN).

## STEP 2 — Rule In / Rule Out
Rule in statin therapy for dyslipidemia if the patient is postmenopausal with elevated LDL-C (≥70 mg/dL) or ASCVD risk indicating need; rule out hormone therapy as first-line lipid-lowering treatment regardless of menopausal symptom status.

## STEP 3 — Classify or Stratify
Stratify by 10‑year ASCVD risk using Pooled Cohort Equations: if risk ≥7.5% consider moderate‑ or high‑intensity statin; if risk 5%–7.4% consider moderate‑intensity statin after risk‑enhancing factor review; if risk <5% prioritize lifestyle unless LDL-C ≥190 mg/dL or familial hypercholesterolemia suspected.

## STEP 4 — Decide
Initiate statin therapy at intensity matched to ASCVD risk (per Step 3) and avoid prescribing hormone therapy solely for lipid improvement; reserve hormone therapy for menopausal symptoms only after shared decision‑making about its cardiovascular risks.

## Clinical Guardrails / Mimics / Pitfalls
Do not use hormone therapy to treat dyslipidemia due to increased VTE and stroke risk; avoid statins in pregnancy, active liver disease, or CK >5×ULN; recognize that hormone therapy may raise triglycerides and precipitate pancreatitis in susceptible women; do not overlook secondary causes of dyslipidemia (hypothyroidism, nephrotic syndrome) before initiating therapy.

## Concrete Clinical Example
A 58‑year‑old postmenopausal woman presents for routine care; lipid panel shows LDL‑C 162 mg/dL, HDL‑C 48 mg/dL, TG 130 mg/dL. She has no prior CVD, no contraindications to statins, and declines hormone therapy for lipids after discussion. A moderate‑intensity statin (atorvastatin 20 mg daily) is started; hormone therapy is not prescribed for lipid management.

**Source:** Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2020, doi:10.1210/clinem/dgaa674